ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q2SCImago #7,582Hybrid

Nuclear Medicine and Biology

Acronym:nucmedbio
•
Abbreviation (ISO):NUCL. MED. BIOL
•
Identifier (ISSN):0969-8051(Print)/1872-9614(Online)
•
Publisher:Elsevier Inc.
Clarivate IF (2026)
3.1↑ +0.1
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Nuclear Medicine and Biology

WoS Q2
12452.220182.4920192.420202.4120212.9520223.120233.62024320253.12026
Annual Impact Factor Metric
Current (2026):3.1
Scopus SJR & RankScopus Q2
0.748
#7,582

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
103

103 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate5.6%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
79articles/year
32.34% Gold OA•98.31% Original Research

Aims & Scope

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

Topics Covered (Recognized by AI)
Chemistry86%Biology82.8%Medicine77.5%Genetics70.4%Biochemistry67.7%Internal medicine61.4%Biotechnology46%In vivo45.1%Organic chemistry42.8%Physics38.9%In vitro37.5%Psychology34.1%Nuclear medicine33.8%Endocrinology29.8%Neuroscience28.8%Radiology27.8%Receptor26.6%Materials science24.9%Biodistribution21.9%Pharmacology21.3%Radiochemistry20.8%

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Q2
Rank70/217
IndexSCIE
JCISCIE2026

RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Q2
Rank55/217
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF3.1
Articles / Year59
Total Citations8
2025
IF3
Articles / Year573
Total Citations158
2024
IF3.6
Articles / Year78
Total Citations396
2023
IF3.1
Articles / Year470
Total Citations352
2022
IF2.947
Articles / Year614
Total Citations720

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #7,582Scopus Q2SCImago Profile
Scopus Coverage:1986-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicine
Scopus Citation Rank (SJR)Q2
0.748

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
2.62

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,052 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations471
3-Year Documents164
Citable Documents153

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate37.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Radiology, Nuclear Medicine and ImagingQ2
Cancer ResearchQ3
Molecular MedicineQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 5.6%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
4区 (Zone 4)Medicine
Minor Category (Specific Field):
4区RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Nuclear Medicine and Biology (acronym: nucmedbio, abbr: NUCL. MED. BIOL, ISSN: 0969-8051) is a peer-reviewed international scholarly journal in the field of Medicine, published by Elsevier Inc. in United States since 1993. The periodical holds a Journal Impact Factor (JIF) of 3.10, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.748 (Q2), an H-index of 103.

The journal enforces rigorous peer evaluation with an average review speed of 8周, a publication frequency of Bimonthly, an annual output of approximately 79 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,052 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Elsevier Inc.
Publication Language
Multi-Language
Frequency
Bimonthly
Founding Year
1993
Indexing & Databases
SCIEScopusPubMed
Editorial Address
ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 67ea919a-1e93-4900-99e4-3d7fd82c43d4
Database Updated: 2026-10-16